MetaCap

IRulya Therapeutics Financial Ratios

NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

39.88-0.06 (-0.15%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IRulya Therapeutics ratio analysis

Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.

Summary generated from market data by MetaCap's automated system. Methodology

IRulya Therapeutics financial ratios (annual)

IRulya Therapeutics annual financial ratios
RatioFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Return on equity (ROE)—-188.5%-36.9%-51.4%-75.8%-44.6%-32.0%—
Return on assets (ROA)-89.8%-49.6%-18.7%-49.7%-67.5%-40.6%-29.7%-17.1%
Debt / equity—0.480.160.00————
Current ratio0.536.058.0930.557.858.1111.9349.82

Related